ArticleFrontiers in ophthalmology2026
Early retinal volume changes after switching to brolucizumab in refractory neovascular age-related macular degeneration.
Article in Frontiers in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This retrospective observational study primarily focused on the evaluation of early anatomical changes and intraocular inflammation (IOI) following the switch to intravitreal injection of brolucizumab (IVBr) in patients with neovascular age-related macular degeneration (nAMD) who were refractory to aflibercept or ranibizumab and unable to extend injection interval beyond 10 weeks while resolving retinal fluids. Results: Data from 23 patients were analyzed. Switch to brolucizumab resulted in rapid decreases in central foveal retinal thickness (CRT) (247 (130) to 227 (94)) μm, P < 0.001), pigment epithelial detachment volume (0.18 (0.47) to 0.11 (0.19) mm³, P = 0.04) and central choroidal thickness (159 (118) to 168 (78) μm, P = 0.018), although decrease in central retinal volume (CRV) (9.80 (1.40) to 9.70 (1.30) mm³, P = 0.111) was not significant.Three eyes exhibited IOI, observed on post-injection day 2 after the second IVBr. Two eyes exhibited only mild anterior chamber inflammation, while one eye exhibited vasculitis obliterans. While CRT decreased, CRV increased in all three eyes.As a Conclusion: Switch to brolucizumab therapy resulted in early anatomical changes. An increase in CRV despite improvement in central foveal parameters may represent a potential warning sign of brolucizumab-associated IOI and warrants further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.